SalubrisBiotherapeutics, the US arm of Shenzhen SalubrisPharma, has negotiated a tech transfer with the US National Institutes of Health for a potential liver cancer drug. The rights are for a bispecific antibody-drug conjugate targeting GPC3, an antigen expressed in liver cancer. According to the NIH, opponents have until August 22 to object to the agreement; otherwise, it will proceed. Some elected US officials oppose these agreements, arguing the US government paid for the basic research, but retains no control over the price the licensee will charge.
Source: ChinaBio Today
